CDC HoST-TT Certification for Siemens Healthineers Total Testosterone Test Expands Patient Access
Siemens Healthineers has announced that its Atellica IM Testosterone II (TSTII) assay has received certification from the CDC Hormone Standardization Program for Total Testosterone (HoSt-TT). This certification ensures that the assay’s results are equivalent to the gold-standard analytical method, high performance liquid chromatography coupled with tandem mass spectrometry. The TSTII assay, which is fully automated and has maintained certification since 2019, plays a critical role in accurately measuring testosterone levels, important for patient diagnosis and treatment.
Tarrytown, NY, USA, May 04, 2026 (GLOBE NEWSWIRE) —
Siemens Healthineers announced its Atellica IM Testosterone II (TSTII) assay has achieved certification through the Centers for Disease Control and Prevention (CDC) Hormone Standardization Program for Total Testosterone (HoSt-TT). This certifies that the Atellica IM TSTII immunoassay’s test results are equivalent to high performance liquid chromatography coupled with tandem mass spectrometry, which is regarded as the gold‑standard analytical approach [1,2]. The Atellica IM TSTII assay, available on the Atellica IM and Atellica CI Analyzers, is the only fully automated immunoassay to achieve CDC HoSt-TT certification, which it has maintained continuously since 2019 [3]. An evaluation of the assay’s performance was recently published in The Journal of Clinical Endocrinology & Metabolism.